Mantle Irradiation for Hodgkin's Disease
- Conditions
- Hodgkin's Disease
- Registration Number
- NCT00165269
- Lead Sponsor
- Dana-Farber Cancer Institute
- Brief Summary
The purpose of this study it to evaluate the effectiveness of radiation therapy limited to above the diaphragm in patients with pathological stage IA-IIA Hodgkin's disease.
- Detailed Description
* Eligble patients will receive a course of radiation therapy directed to above the diaphragm only.
* Patients would have bloodwork and chest x-rays performed 4 times per year for the first two years, 3 times per year for the third year, and 2 times per year for the fourth and fifth years. After five years, yearly check-ups are performed.
* In addition to the above follow-up, patients will receive, once or twice a year for the first 5 years, an abdominal-pelvic CT scan and/or gallium scan.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Pathologically Stage IA-IIA Hodgkin's disease
- A negative staging laparotomy including splenectomy, biopsies of liver, paraortic nodal biopsies and palpitation of upper pelvic nodes
- 18 years of age or older
- Patients with large mediastinal adenopathy
- Patients with LD histology
- Patients with "B" symptoms
- Positive laparotomy
- Subcarinal, hilar, or cardiac lymph node involvement
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To evaluate the risks and benefits of mantle field irradiation alone in treating Hodgkin disease patients. 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Dana-Farber Cancer Center
🇺🇸Boston, Massachusetts, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States